Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial

Objective To determine whether a combination of a selective serotonin reuptake inhibitor (SSRIs) and cognitive behaviour therapy (CBT) together with clinical care is more effective in the short term than an SSRI and clinical care alone in adolescents with moderate to severe major depression. Design Pragmatic randomised controlled superiority trial. Setting 6 outpatient clinics in Manchester and Cambridge. Participants 208 adolescents, aged 11-17, with moderate to severe major or probable major depression who had not responded to a brief initial intervention. Adolescents with suicidality, depressive psychosis, or conduct disorder were included. Interventions 103 adolescents received an SSRI and routine care; 105 received an SSRI, routine care, and CBT. The trial lasted 12 weeks, followed by a 16 week maintenance phase. Main outcome measures Change in score on the Health of the Nation outcome scales for children and adolescents (primary outcome) from baseline with 12 weeks as the primary and 28 weeks as the follow-up end point. Secondary measures were change in scores on the mood and feelings questionnaire, the revised children's depression rating scale, the children's global assessment scale, and the clinical global impression improvement scale. Results At 12 weeks the treatment effect for the primary outcome was −0.64 (95% confidence interval −2.54 to 1.26, P=0.50). In a longitudinal analysis, there was no difference in effectiveness of treatment for the primary (average treatment effect 0.001, −1.52 to 1.52, P=0.99) or secondary outcome measures. On average there was a decrease in suicidal thoughts and self harm. There was no evidence of a protective effect of cognitive behaviour therapy on suicidal thinking or action. By 28 weeks, 57% were much or very much improved with 20% remaining unimproved. Conclusions For adolescents with moderate to severe major depression there is no evidence that the combination of CBT plus an SSRI in the presence of routine clinical care contributes to an improved outcome by 28 weeks compared with the provision of routine clinical care plus an SSRI alone. Trial registration Current Controlled Trials ISRCNT 83809224.

[1]  Golda S. Ginsburg,et al.  Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  C. Roberts,et al.  Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. , 2006, The British journal of psychiatry : the journal of mental science.

[3]  B. Tonge,et al.  A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[4]  I. Goodyer,et al.  Longitudinal investigation into childhood-and adolescence-onset depression: Psychiatric outcome in early adulthood , 2006, British Journal of Psychiatry.

[5]  J. Powell,et al.  A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  Benedetto Vitiello,et al.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. , 2004, JAMA.

[7]  Peter Fonagy,et al.  Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data , 2004, The Lancet.

[8]  N. Bilenberg Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) , 2003, European child & adolescent psychiatry.

[9]  E. Fombonne,et al.  The Maudsley long-term follow-up of child and adolescent depression , 2001, British Journal of Psychiatry.

[10]  J. Dyrborg,et al.  The Children's Global Assessment Scale (CGAS) and Global Assessment of Psychosocial Disability (GAPD) in clinical practice – substance and reliability as judged by intraclass correlations , 2000, European Child & Adolescent Psychiatry.

[11]  C. Roberts,et al.  The implications of variation in outcome between health professionals for the design and analysis of randomized controlled trials. , 1999, Statistics in medicine.

[12]  P. Lelliott,et al.  Brief scale for measuring the outcomes of emotional and behavioural disorders in children , 1999, British Journal of Psychiatry.

[13]  R. Harrington,et al.  Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder , 1998, BMJ.

[14]  B. Everitt,et al.  Analysis of longitudinal data , 1998, British Journal of Psychiatry.

[15]  N. Ryan,et al.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  J. Mintz,et al.  Implications of therapist effects for the design and analysis of comparative studies of psychotherapies. , 1991, Journal of consulting and clinical psychology.

[17]  K. Dobson,et al.  The Cognitive Therapy Scale: psychometric properties. , 1986, Journal of consulting and clinical psychology.

[18]  R. Gibbons,et al.  Preliminary studies of the reliability and validity of the children's depression rating scale. , 1984, Journal of the American Academy of Child Psychiatry.

[19]  Nice Depression: management of depression in primary and secondary care , 2005 .

[20]  S Iyengar,et al.  Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. , 2000, Archives of general psychiatry.